Combined-modality 125J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects-Reference-Cited by-同舟云学术

Combined-modality 125J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects

Published:2019-02-01 Issue:11 Volume:37 Page:2355-2363
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Boehle A.^ORCID,Katic K.,König I. R.,Robrahn-Nitschke I.,Renner P.,Brandenburg B.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/article/10.1007/s00345-019-02649-2/fulltext.html

Reference32 articles.

1. Bittner N, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, Wallner KE (2012) Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy 11(4):250–255. https://doi.org/10.1016/j.brachy.2012.02.002

2. Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M (2012) Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 61(3):584–592. https://doi.org/10.1016/j.eururo.2011.11.043

3. Muralidhar V, Xiang M, Orio PF 3rd, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL (2016) Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy 8(1):1–6. https://doi.org/10.5114/jcb.2016.58080

4. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N (2017) Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):275–285. https://doi.org/10.1016/j.ijrobp.2016.11.026

5. Ennis RD, Hu L, Ryemon SN, Lin J, Mazumdar M (2018) Brachytherapy-based radiotherapy and radical prostatectomy are associated with similar survival in high-risk localized prostate cancer. J Clin Oncol 36(12):1192–1198. https://doi.org/10.1200/JCO.2017.75.9134

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients;Urologic Oncology: Seminars and Original Investigations;2023-11

2. Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?;Advances in Radiation Oncology;2023-03

3. Evaluation einer Prostatakrebsnachsorge-App aus Patientensicht: Eine qualitative Studie;Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen;2022-12

4. Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy;Brachytherapy;2020-01